Soligenix on IDR technology and SGX942
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
List view / Grid view
Articles
Advancing FLIP inhibitors for the treatment of NSCLC
26 April 2016 | By Victoria White, Drug Target Review
In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
The threat of antibiotic resistance
25 April 2016 | By Victoria White, Drug Target Review
We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...
Demands in medical automation technology brings two prominent players close
22 April 2016 | By Snehal Chougule, Allied Market Research
Here, Snehal Chougule discusses Trajan's recent investment in automation solution company, LEAP Technologies Inc...
Delving into drug discovery in Drug Target Review
12 April 2016 | By Caroline Richards, Editor, Drug Target Review
Here, Caroline Richards, Editor of Drug Target Review, discusses the publication and the opportunities available to authors...
Our EU referendum poll: the results are in
31 March 2016 | By Victoria White, Drug Target Review
We asked readers of if they agreed with BIA that the UK pharmaceutical industries are stronger in the EU. The results of that poll are now in...
Explaining CAR T-cell therapy
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
Drug Target Review – Issue #1 2016
17 March 2016 | By Drug Target Review
Included in this issue: Microfluidics, Protein Expression, Drug Targets, Biomarkers, Oncology, Assays, Antibodies, and much more...
Antibodies In-Depth Focus 2016
In this Antibodies In-depth Focus: Antibody fragment technology and avian IgY antibodies: a powerful combination; plus the challenges with antibody-based targeting of VEGF...
Assays In-Depth Focus 2016
In this Assays In-Depth Focus: "Finding a cure for neglected tropical diseases with cell-based assays", plus "The relevance of homogeneous radiometric assays in modern drug discovery"...
Using computational models to aid drug discovery
Long term success for pharmaceutical businesses depends upon harnessing the best tools available to bring safe and effective medicines to market at a competitive price, and to be truly successful, for such drugs to be first in class.
Drug Targets In-Depth Focus 2016
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
Interview with Amrik Basran, Chief Scientific Officer at Avacta Life Sciences
Caroline Richards, Editor of Drug Target Review, asks Amrik Basran, Chief Scientific Officer at Avacta Life Sciences, to provide his views on Affimer® technology...
Microfluidics: The fur-free way towards personalised medicine in cancer therapy
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal models in the testing of medicines and in developing personalised treatments for cancer patients.
Pushing the limits of protein expression with miRNAs
Biopharmaceuticals are highly complex protein drugs such as antibodies, cytokines and peptide hormones, which are used for a variety of indication areas, including immunology, neurology, metabolic diseases and cancer. These modern protein drugs may hinder progression of a disease, ease symptoms or assure – in the case of chronic diseases…
